Mi SciELO
Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Citado por Google
- Similares en SciELO
- Similares en Google
Compartir
Ars Pharmaceutica (Internet)
versión On-line ISSN 2340-9894
Resumen
SOTOCA-MOMBLONA, José Miguel y ROVIRA-ILLAMOLA, Marina. Drug use evaluation of nirmatrelvir/ritonavir in three primary care centres during 2022. Ars Pharm [online]. 2023, vol.64, n.4, pp.342-347. Epub 08-Ene-2024. ISSN 2340-9894. https://dx.doi.org/10.30827/ars.v64i4.28499.
Introduction:
Nirmatrelvir/ritonavir (Paxlovid®) is the only oral treatment authorized in Europe to treat COVID-19 disease in adults who do not require supplemental oxygen and who are at high risk for progression to severe COVID-19.
It is available in Spain after validation due to the profile of interactions and warnings for use.
The objective is to determine effectiveness, safety and management of interactions.
Method:
Retrospective study of all patients on validated nirmatrelvir/ritonavir treatment at three urban health centres during 2022. Effectiveness was the proportion of participants without COVID-19-related hospitalization or death from any cause through day 28.
Results:
24 patients were analyzed. It was considered effective in 23 (95.8 %). More than 80 % of patients presented potential interaction with the concomitant medication, recommending the temporary suspension of medications, highlighting simvastatin and metamizole.
Conclusions:
Nirmatrelvir/ritonavir has been considered effective but difficult to manage in polymedicated polypathological patients.
Palabras clave : COVID-19; nirmatrelvir/ritonavir; primary care; drug use evaluation; effectiveness.